Literature DB >> 1923355

Immunopathology of atopic keratoconjunctivitis.

C S Foster1, B A Rice, J E Dutt.   

Abstract

Conjunctival biopsies from 11 patients with atopic keratoconjunctivitis (AKC) and from 13 age-matched healthy individuals undergoing cataract surgery were analyzed by light microscopy and immunohistochemical techniques. Histology of AKC specimens showed goblet cell proliferation, epithelial pseudotubular formation, eosinophil and mast cell invasion of the epithelium, and pronounced mononuclear cell infiltration of the substantia propria, often with frank granuloma formation. Epithelium of AKC conjunctiva showed significantly more T cells (CD3+, CD5+), T-helper cells (CD4+), macrophages (Mac-1+, CD14+), activated T cells, (CD25+), and dendritic cells (CD1+), and a higher helper/suppressor ratio than did control subjects. In the substantia propria, AKC specimens showed dramatically increased inflammatory cell infiltration with significantly more cells staining, in order of frequency, for T-cells (CD3+, CD5+), T-helper cells (CD4+), T-suppressor/cytotoxic cells (CD8+), macrophages (CD14+, Mac-1+) activated T cells (CD25+), B cells (CD22+), and dendritic cells (CD1+, HLA-DR+). Fifty-three percent of T cells in the substantia propria expressed the interleukin-2 receptor protein (CD25+). These findings indicate that the chronic conjunctivitis of AKC is complex, with activated T-cells and macrophages dramatically participating in the process. Successful long-term control of the potentially binding conjunctival inflammation of this disease is likely to require therapeutic strategies directed toward more than just the mast cell component of the process.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1923355     DOI: 10.1016/s0161-6420(91)32154-7

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  21 in total

1.  A comparison of the inhibitory activity of PDE4 inhibitors on leukocyte PDE4 activity in vitro and eosinophil trafficking in vivo.

Authors:  N Cooper; M M Teixeira; J Warneck; J M Miotla; R E Wills; D M Macari; R W Gristwood; P G Hellewell
Journal:  Br J Pharmacol       Date:  1999-04       Impact factor: 8.739

Review 2.  Ocular mast cells. Characterization in normal and disease states.

Authors:  E B Cook; J L Stahl; N P Barney; F M Graziano
Journal:  Clin Rev Allergy Immunol       Date:  2001-04       Impact factor: 8.667

3.  Development of organised conjunctival leucocyte aggregates after corneal transplantation in rats.

Authors:  S Banerjee; F C Figueiredo; D L Easty; A D Dick; S M Nicholls
Journal:  Br J Ophthalmol       Date:  2003-12       Impact factor: 4.638

Review 4.  Allergic eye disease mechanisms.

Authors:  J I McGill; S T Holgate; M K Church; D F Anderson; A Bacon
Journal:  Br J Ophthalmol       Date:  1998-10       Impact factor: 4.638

Review 5.  Topical ciclosporin in the treatment of ocular surface disorders.

Authors:  S Tatlipinar; E K Akpek
Journal:  Br J Ophthalmol       Date:  2005-10       Impact factor: 4.638

6.  The value of biopsies in the evaluation of chronic progressive conjunctival cicatrisation.

Authors:  W Bernauer; M J Elder; J N Leonard; P Wright; J K Dart
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1994-09       Impact factor: 3.117

7.  Effects of phosphodiesterase isoenzyme inhibitors on cutaneous inflammation in the guinea-pig.

Authors:  M M Teixeira; A G Rossi; T J Williams; P G Hellewell
Journal:  Br J Pharmacol       Date:  1994-05       Impact factor: 8.739

8.  Cytokines in the conjunctiva of acute and chronic mucous membrane pemphigoid: an immunohistochemical analysis.

Authors:  W Bernauer; P Wright; J K Dart; J N Leonard; S Lightman
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1993-10       Impact factor: 3.117

9.  Concentration of soluble interleukin-6 receptors in tears of allergic conjunctival disease patients.

Authors:  Jun Shoji; Atsuri Kawaguchi; Aki Gotoh; Noriko Inada; Mitsuru Sawa
Journal:  Jpn J Ophthalmol       Date:  2007-10-05       Impact factor: 2.447

Review 10.  Therapeutic options in ocular allergic disease.

Authors:  M Hingorani; S Lightman
Journal:  Drugs       Date:  1995-08       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.